Imunon, Inc. (0HUZ.L)

1.4000 +0.0657 (+4.92%) At close: 05:40PM BST

Imunon, Inc.

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100
https://www.imunon.com

Sector(s): 
Industry: 
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael H. Tardugno	Executive Chairman	N/A	N/A	1951
Mr. Jeffrey W. Church CPA	CFO, Executive VP & Corporate Secretary	632.02k	N/A	1957
Dr. Khursheed Anwer M.B.A., Ph.D.	Executive VP & Chief Scientific Officer	632.26k	N/A	1960
Mr. Timothy J. Tumminello CPA	Chief Accounting Officer & Controller	108.31k	N/A	1958
Ms. Marianne M. Lambertson	Vice President of Communications & Investor Relations	N/A	N/A	N/A
Dr. Sebastien Hazard M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. It also develops ThermoDox, a direct chemotherapy. In addition, the company is developing IMNN-101, a COVID-19 booster vaccine which is in preclinical trials; IMNN-102 for the of the Lassa virus which is in preclinical trials; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. Further, it develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Corporate governance

Imunon, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.